Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: Randomised controlled trial in four European countries

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Patel, Anita ^a   McCrone, Paul ^a   Leese, Morven ^a   Amaddeo, Francesco ^b   Tansella, Michele ^b   Kilian, Reinhold ^c   Angermeyer, Matthias ^d   Kikkert, Martijn ^e   Schene, Aart ^f   Knapp, Martin ^a,g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF ULM   (Germany)

^d Center for Public Mental Health   (Austria)

^e Arkin Mental Health Care Institution   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Adherence; Antipsychotic; Cost effectiveness; Psychological therapy; Quality adjusted life year; Schizophrenia

Indexed keywords

ADHERENCE THERAPY; ADULT; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRIMINAL JUSTICE; EUROPE; FEMALE; HEALTH CARE COST; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SHORT FORM 36; SOCIAL CARE;

EID: 84878006395     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-12     Document Type: Article

References (29)

1. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004, 30(2):279-293. 10.1093/oxfordjournals.schbul.a007078, 15279046.
2. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004, 184:509-516. 10.1192/bjp.184.6.509, 15172945.
3. David A. Treatment adherence in psychoses. Br J Psychiatry 2010, 197:431-432. 10.1192/bjp.bp.110.083022, 21119147.
4. Gray R, Leese M, Bindman J, Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, Schene A, Thornicroft G, Tansella M. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 2006, 189:508-514. 10.1192/bjp.bp.105.019489, 17139034.
5. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999, 18(3):341-364. 10.1016/S0167-6296(98)00039-3, 10537899.
6. Claxton K, Sculpher M, Drummond D. A rational framework for decision making by the national institute for clinical excellence (NICE). Lancet 2002, 360(9334):711-715. 10.1016/S0140-6736(02)09832-X, 12241891.
7. Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B, and the EPSILON Study Group Client Socio-demographic and Service Receipt Inventory - EU version: development of an instrument for international research. Br J Psychiatry 2000, 177(Suppl 39):28-33. and the EPSILON Study Group.
8. Chisholm DH. Cross-cultural mental health care evaluation: developing and demonstrating methods for economic analysis 2001, London: PhD Thesis. Institute of Psychiatry, King's College London, University of London.
9. OECD Purchasing power parities, comparative price levels 2005, http://www.oecd.org/std/ppp (accessed 12 September 2005), OECD.
10. Patel A. Conducting and interpreting multi-national economic evaluations: the measurement of costs. Unit costs of health & social care, 2006 2006, 9-15. Canterbury, England: University of Kent, Curtis L, Netten A.
11. OECD Economic outlook 77 database. Annex table 16. GDP deflators 2005, http://www.oecd.org/document/61/0,2340,en_2825_495691_2483901_1_1_1_1,00.html] (accessed 12 September 2005), OECD.
12. OECD. OECD Economic outlook 90 database Annex table 1. Real GDP 2011, http://www.oecd.org/dataoecd/6/27/2483806.xls (accessed 16 December 2011), OECD. OECD Economic outlook 90 database.
13. Ware J, Sherbourn C. The MOS, 36 item short-form health survey (SF-36). I conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
14. McCrone P, Patel A, Knapp M, McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, Ruggeri M, Giessler A, Puschner B, Thornicroft G. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009, 12:27-31.
15. The EuroQol Group EuroQol: a facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
16. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292. 10.1016/S0167-6296(01)00130-8, 11939242.
17. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK population survey 1995, York, England: University of York.
18. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005, 14:487-496. 10.1002/hec.944, 15497198.
19. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999, 8:257-261. 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E, 10348420.
20. SPSS Inc SPSS for windows release 12.0.1 2003, Chicago, USA: SPSS Inc, 1989-2003, SPSS Inc.
21. StataCorp LP STATA 8.2 for windows 2003, Texas, USA: StataCorp LP, 1985-2003, StataCorp LP.
22. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000, 355:1064-1069. 10.1016/S0140-6736(00)02039-0, 10744093.
23. Staring ABP, Van der Gaag M, Koopmans GT, Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2010, 197:448-455. 10.1192/bjp.bp.110.077289, 21119150.
24. Andrews A, Knapp M, McCrone P, Parsonage M, Trachtenberg M. Effective interventions in schizophrenia the economic case: a report prepared for the schizophrenia commission 2012, London, England: Rethink Mental Illness.
25. Kemp R, Kirov G, Everitt B, Hayward P, David A. A randomised controlled trial of compliance therapy: 18 months follow-up. Br J Psychiatry 1998, 172:419.
26. Healey A, Knapp M, Astin J, Healey A, Knapp M, Astin J, Beecham J, Kemp R, Kirov G, David A. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry 1998, 172:420-424. 10.1192/bjp.172.5.420, 9747404.
27. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007, 10:23-41.
28. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003, 37(5):625-630.
29. King D, Knapp M, Patel A, King D, Knapp M, Patel A, Amaddeo F, Tansella M, Schene A, Koeter M, Angermeyer M, Becker T. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol Psychiatr Sci 2013, 10:1-10.